Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

New England Journal of Medicine

Volumn 362, Issue 10, 2010, Pages 875-885

  Steidl, Christian ^a   Lee, Tang ^a   Shah, Sohrab P ^a   Farinha, Pedro ^a   Han, Guangming ^a   Nayar, Tarun ^a   Delaney, Allen ^a   Jones, Steven J ^a   Iqbal, Javeed ^b   Weisenburger, Dennis D ^b   Bast, Martin A ^b   Rosenwald, Andreas ^c   Muller Hermelink, Hans Konrad ^c   Rimsza, Lisa M ^d   Campo, Elias ^e   Delabie, Jan ^f   Braziel, Rita M ^g   Cook, James R ^h,i   Tubbs, Ray R ^h,i   Jaffe, Elaine S ^j   Lenz, Georg ^j   Connors, Joseph M ^a   Staudt, Louis M ^j   Chan, Wing C ^b   Gascoyne, Randy D ^a   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF BARCELONA   (Spain)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

EID: 77949345555     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0905680     Document Type: Article

References (34)

1. Björkholm M, Axdorph U, Grimfors G, et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease: a prospective randomized trial. Ann Oncol 1995;6:895-9.
2. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
3. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program 2003: 225-47.
4. Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339: 1506-14.
5. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.
6. Sup SJ, Alemany CA, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005;23:3773-9.
7. Doussis-Anagnostopoulou IA, Vassila- kopoulos TP, Thymara I, et al. Topoisomerase IIalpha expression as an independent prognostic factor in Hodgkin's lymphoma. Clin Cancer Res 2008;14:1759-66.
8. Natkunam Y, Lossos IS, Taidi B, et al. Expression of the human germinal centerassociated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood 2005;105:3979-86.
9. Diepstra A, van Imhoff GW, Karim- Kos HE, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007; 25:3101-8.
10. Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467-73.
11. Alvaro-Naranjo T, Lejeune M, Salvadó- Usach MT, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 2005;46: 1581-91.
12. Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007; 128:958-65.
13. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193-200.
14. Krishnapuram B, Carin L, Figueiredo MA, Hartemink AJ. Sparse multinomial logistic regression: fast algorithms and generalization bounds. IEEE Trans Pattern Anal Mach Intell 2005;27:957-68.
15. Breiman L. Random forests. Mach Learn 2001;45:5-32.
16. Shaffer AL, Wright G, Yang L, et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 2006;210: 67-85.
17. Duff MD, Mestre J, Maddali S, Yan ZP, Stapleton P, Daly JM. Analysis of gene expression in the tumor-associated macrophage. J Surg Res 2007;142:119-28.
18. Su AI, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004;101:6062-7.
19. Lenz G, Wright G, Dave SS, et al. Strom-al gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-23.
20. Urs S, Smith C, Campbell B, et al. Gene expression profiling in human preadipocytes and adipocytes by microarray analysis. J Nutr 2004;134:762-70.
21. Karube K, Ohshima K, Suzumiya J, Kawano R, Kikuchi M, Harada M. Gene expression profile of cytokines and chemokines in microdissected primary Hodgkin and Reed-Sternberg (HRS) cells: high expression of interleukin-11 receptor alpha. Ann Oncol 2006;17:110-6.
22. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006;354:2431-42.
23. Sánchez-Aguilera A, Montalbán C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006;108:662-8.
24. Devilard E, Bertucci F, Trempat P, et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 2002;21:3095-102.
25. Odaka C, Izumiyama S. Expression of stromelysin-3 (matrix metalloproteinase-11) in macrophages of murine thymus following thymocyte apoptosis. Cell Immunol 2005;235:21-8.
26. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009;113:2765-3775.
27. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69.
28. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-74.
29. Mantovani A, Sozzani S, Locati M, Al-lavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
30. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.
31. Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;113: 5920-6.
32. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-4.
33. Falchi L, Capello D, Palumbo B, et al. A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy. Eur J Haematol 2007;79:455-61.
34. Perz JB, Giles C, Szydlo R, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant 2007;39:41-7.